Objective Our objective was to retrospectively evaluate whether the levels of cell-free DNA (cfDNA) fetal fraction differed in the first trimester of pregnancies between controls and those who subsequently developed early-or late-onset fetal growth restriction (FGR). Methods This was a case-control study conducted between May 2015 and May 2018 in 231 low-risk women who had received first trimester screening for major fetal aneuploidies (Panorama, Natera, San Carlos, CA, USA). Early-and lateonset FGR developed in 5 and 16 women, respectively, according to Delphi criteria. Multiples of median (MoM) were used to evaluate the differences in cfDNA fetal fraction between cases and controls. cfDNA fetal fraction was adjusted for gestational age (from 10 + 0 to 13 + 6 gestational weeks) and maternal weight (43-96 kg Conclusions Low-risk pregnancies that developed early-onset FGR had lower cfDNA fetal fractions than did the matched controls. This result is consistent with the placental dysfunction typical of early-onset FGR. For possible clinical use, the cfDNA fetal fraction would yield a better predictive value if adjusted for maternal weight, since maternal weight affects both cfDNA fetal fraction and the occurrence of FGR.
Introduction
Cell-free DNA (cfDNA) testing for chromosomal abnormalities based on circulating cell-free fetal DNA (cffDNA) has been clinically available since 2011 and exhibits high accuracy for the detection of trisomy 21 in both high-risk and general populations [1] ; it is now available globally, largely through the private sector. The total cfDNA in a pregnant woman comprises predominantly maternal DNA derived from the mother's hematopoietic system [2] and fetal DNA released through apoptosis of cytotrophoblast cells during fetal development [3] . The proportion of total cfDNA belonging to the fetus (fetal fraction) is a paramount factor in determining the accuracy of cfDNA testing, which is higher when the fetal fraction is high [4] . Fetal growth restriction (FGR) is one of the most common causes of poor perinatal and long-term outcomes [5] . FGR is not easy to classify, and fetal smallness, i.e., an estimated fetal weight (EFW) < 10th centile, remains the best universally accepted criterion. However, many other parameters, including the time at which FGR became apparent (before or after 32 weeks' gestation), fetal abdominal circumference (AC) centile and Doppler indices (including uterine artery pulsatility index [UtA-PI] and umbilical artery pulsatility index [UA-PI]), have been included in the FGR classification [6, 7] . Based on the so-called Delphi procedure and a set of specific criteria [6] , two major phenotypes of FGR can be identified: early-and late-onset FGR, which occur before or after 32 weeks of gestation, respectively. Placental insufficiency is univocally considered a major cause of FGR and poorer perinatal outcomes [8] . The challenges of predicting FGR have led to new screening methods in recent years; these are based on the early identification of placental insufficiency, which involves the dosage of placental biochemical products, including placental growth factor (PlGF), pregnancy-associated plasma protein A (PAPP-A) and Doppler measurements [9, 10] . Moreover, based on previous, but unfortunately inconclusive, observations that associated aberrant maternal circulating cffDNA concentrations with preeclampsia (where a defective placenta is present) [11] [12] [13] [14] [15] [16] and FGR [5, 14, 15] , researchers are now considering whether a lower cfDNA fetal fraction could also serve as an early marker of a defective placenta and therefore be useful in FGR screening.
We evaluated whether the cfDNA fetal fraction determined at the time of the first trimester screening for fetal aneuploidies was lower than expected in low-risk pregnancies that developed early-and late-onset FGR later in pregnancy compared with a population of controls.
Materials and Methods
We used the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist of items that should be addressed.
Study Design
We conducted a retrospective cohort study of nonconsecutive patients between May 2015 and May 2018, including 231 pregnant women who had undergone DNA testing based on circulating cffDNA as a primary or secondary screening test for fetal chromosomal abnormalities, at 10 + 0 to 13 + 0 gestational weeks. The study was carried out following the ethical rules of Sant'Orsola-Malpighi General Hospital, Bologna, Italy (approved by the local ethics committee: DBPP13EPP).
Setting
A Panorama test kit consisting of two Streck™ tubes for maternal blood collection provided by Natera (San Carlos, CA, USA) was used for all tests. Blood samples (20 ml) were taken from the patients by a local gynecologist and sent overnight to Synlab Italia (Vicenza, Italy). All samples were shipped via airfreight to the Natera laboratory in San Carlos, CA, USA, and arrived within 48 h. The samples were processed and analyzed at Natera's certified laboratory using validated methodologies for cfDNA isolation. If the first sample did not meet the required quality criteria, e.g., for low cfDNA fetal fraction, the patient was excluded from the study. Informed consent was given by patients before data were entered into a dedicated database. These consents were kept by the private center in which the blood test was carried out (Poliambulatorio SaluSanGiorgio, San Giorgio di Piano, Bologna, Italy) and by Synlab Italia (Brescia, Italy). The women who opted to have cffDNA testing before 11 weeks' gestation underwent ultrasound examination before the blood sampling to confirm pregnancy viability and exclude multiple pregnancies, and a fetal structural evaluation was suggested between 11 + 0 and 13 + 6 weeks' gestation. In all cases, gestational age was calculated based on the fetal crown-rump length (CRL) at 11 to 13 + 0 weeks' gestation. The patients did not have any biochemical screening at the first trimester for preeclampsia and/or FGR (not performed in our hospital), but higher-risk patients were identified via analysis of maternal characteristics and medical history and measurement of maternal weight and height.
All examinations were performed by experienced physicians (DM, SR, AF) using a GE Voluson E8 (GE Healthcare, Milan, Italy) ultrasound machine equipped with a 6-12-MHz linear curved-array transducer. DM is also a qualified operator at the "Fetal Medicine Foundation" in London.
To be included, patients had to present with a normal single pregnancy without any known clinical complications at the time of blood test and informed consent. The participants were selected if a complete followup of the pregnancy was available. Exclusion criteria were as follows: lack of follow-up, maternal body mass index (BMI) < 18.5 or > 30 at the time of enrollment, pre-pregnancy diabetes, gestational diabetes, neonatal macrosomia (> 90th centile for gestational age at delivery), chronic hypertension, vanishing twin, fetal malformations, abnormal fetal karyotype, cfDNA fetal fraction < 4% and a risk score for aneuploidy ≥ 1:100 as estimated by the Natera bioinformatics-based algorithm, called Next-generation Aneuploidy Testing Using SNPs (NATUS). Fetal fractions < 4% were excluded since we started collecting data when the fetal fraction of 4% was the accepted cut-off for a reliable result. However, it should be noted that a value < 2.8% is currently accepted as the threshold for "no result" [17] .
Sample Size
The power analysis for a comparison of two independent means was carried out using Power Analysis Sample Size (PASS) software (Kaysville, UT, USA). Since it was a retrospective study, that analysis was carried out at the end of the enrollment. It was estimated that, in total, five cases and 175 controls (given an arbitrary sample allocation ratio of 1:35 and a coefficient of cfDNA fetal fraction variation expressed as standard deviation [SD]/mean = 0.25), would be able to detect a decrease in the cfDNA fetal fraction of at least 30% between the groups, with a type I error of 5% and a power of 80%.
Statistics
The mean ± SD cfDNA fetal fraction was calculated for each available variable in both the cases and the control samples. The cfDNA fetal fraction values were converted into multiples of median (MoM) by dividing the actual value of the cfDNA fetal fraction observed by the median expected values of the controls (estimated by a log-linear equation with gestational age as an independent variable). The influence of maternal weight on cfDNA fetal fraction levels was explored and adjusted using the method described by Neveux et al. [18] . Non-parametric analyses (χ 2 test and Marascuilo procedure, Kruskal-Wallis test and Dunn post hoc test) were used to detect the differences between cases and controls. A rank analysis matching each case of early-onset FGR with 135 controls in a 1:35 ratio was also carried out. To reduce overestimation of the FGR effect, the lowest cfDNA fetal fraction value for FGR cases was matched with the 35 lowest values for controls and so on until the enrollment of the five FGR cases.
A Delphi procedure [6] was used to classify fetuses as early-or late-onset FGR. Following this classification, early-onset FGR occurred at < 32 weeks' gestation with an AC < 3rd centile or EFW < 3rd centile, or absent/reversed umbilical artery end diastolic flow, or both of the following: (1) EFW or AC < 10th centile and (2) UtA-PI > 95th centile or UA-PI > 95th centile. Late-onset FGR occurred at > 32 weeks' gestation with an AC < 3rd centile or EFW < 3rd centile, or at least two out of three of the following: (1) AC or EFW < 10th centile, (2) AC/EFW crossing centiles > 2 quartiles on growth centiles, (3) cerebroplacental ratio (CPR) < 5th centile or UA-PI > 95th centile.
Results
Of data for 255 women retrospectively collected at the Poliambulatorio SaluSanGiorgio, 45 were excluded because they did not meet inclusion criteria. There were 23 cases of gestational diabetes, 20 cases of neonatal macrosomia (neonatal weight > 90 centile for gestational age at delivery) and two cases of fetal malformations. In total, we enrolled 210 women carrying a single fetus with an uncomplicated pregnancy, five women with early-onset FGR and 16 women with late-onset FGR. Table 1 shows the baseline demographics and clinical outputs. In early-onset FGR, one case had early preeclampsia (requiring delivery < 34 weeks) and one case had late preeclampsia (requiring delivery > 34 weeks). The patient group with early-onset FGR also had a significantly lower gestational age at delivery. Although the women with FGR had a lower weight, the difference was not significant in comparison with controls. The cfDNA fetal fraction MoM values were correlated with maternal weight, as shown in Fig. 1 , allowing an additional adjustment as reported in Sect. 2. The median cfDNA fetal fraction for the controls and early-and late-onset FGR was 1.00 (IQR 0.89-1.12), 0.69 (IQR 0.44-0.84) and 0.93 (IQR 0.83-1.03) MoM, respectively, as reported in Table 2 . Statistically lower cfDNA fetal fraction MoM values were observed only in patients with early-onset FGR (Kruskal-Wallis test with Dunn-Bonferroni post hoc test). In rank sum analysis, the mean value of 2.00 ± 2.23 in the early-onset FGR cases was significantly lower than the expected 18.97 ± 10.17 (p < 0.001). Figure 2 shows the MoM value stratified according to each set of data (comprising 1 case and 35 controls each). The FGR cases with preeclampsia (one case of early preeclampsia labeled with Δ and one case of late preeclampsia labeled with∇) are also reported. As shown for each set, one of the 35 controls always has the value 1, which represents the median (1 MoM) for that specific set. As expected, the two cases that also had preeclampsia scored among the lowest cfDNA fetal fraction values (case identification numbers 1 and 3, respectively). Given the lack of statistical differences, the rank analysis for late-onset FGR was not carried out.
Discussion
Our study found that, in a low-risk population and fetuses that were low risk according to cfDNA testing for major fetal aneuploidies, a lower cffDNA was detected in earlyonset but not late-onset FGR. These findings supported the hypothesis that lower fetal fraction may be the consequence of a smaller placental mass and even an early sign of placental dysfunction. Our results are also in line with those of Rolnik et al. [19] , who showed an association between specific biophysical and biochemical markers for preeclampsia (including mean arterial pressure [MAP] , uterine artery Doppler, PlGF and PAPP-A) with cfDNA fetal fraction. Our results indicated, for the first time, that the cfDNA fetal fraction is lower in early-onset FGR cases and that it could potentially serve as an extra screening marker in a combined screening model. However, since a significant degree of overlapping with other markers of placental dysfunction (PAPP-A, PlGF, UA-PI) is highly likely, only prospective studies could validate whether cfDNA fetal fraction can really be clinically useful in improving detection rates and the predictive positive value for FGR. Our results indicate its potential role seems to be limited to early FGR cases, which represent the minority of all FGR. This is also consistent with the etiopathogenesis of early FGR, which is associated with more severe placental disease, preeclampsia, and escalating abnormalities in Doppler parameters, often necessitating preterm delivery. In contrast, in late-onset FGR, normal or minimally elevated Doppler indices (but abnormal CPR) are present, and there is a weak association with preeclampsia. It is worth noting that previous studies from our group [20] [21] [22] showed higher fetal DNA levels for FGR and preeclampsia. These findings have been attributed to an abnormal increase in villous trophoblast apoptosis as a result of placental ischemia, the release of cellular debris containing fetal DNA, which stimulates the inflammatory nature of vascular and end-organ damage [23, 24] , and reduced clearance of cfDNA from the maternal kidney [25] . Another source of fetal DNA in FGR could be represented by the presence of a higher number of circulating fetal erythroblasts due to fetal hypoxia stimulating the production of erythropoietin in fetal circulation [26] . The apparent contradiction (lower fetal fraction as opposed to an increase in the absolute quantities of fetal cfDNA) could partially be explained by evidence that, at least in preeclampsia, a less pronounced increase in fetal cfDNA compared with maternal cfDNA has been observed [12, 27] , with a consequent reduction in fetal fraction. Maternal DNA was also found to be twofold higher than expected at the third trimester of pregnancy in FGR [28] , probably because a similar mechanism takes place. The adjustment for maternal weight (not carried out in previous studies on fetal DNA) can be an extra reason for such a discrepancy between lower fetal fraction and absolute cfDNA quantities.
Finally, it should be pointed out that unexplained high levels of circulating maternal DNA and lower cfDNA were found in pregnancies affected with fetal Down syndrome in the first trimester [29] and trisomy 18 [30] in the second trimester, respectively, showing that fetal aneuploidies may have an impact on circulating maternal DNA and cfDNA quantities. 
Limitations of the Study
Even if a sample size analysis had been carried out to detect the power of the study, the number of cases was still quite small and the cfDNA fetal fraction could not be stratified according to the criteria of early-or late-onset FGR Delphi classification. Furthermore, two cases of early-onset FGR also had preeclampsia, which introduced a bias in cfDNA fetal fraction values because of the possible concomitant effect of preeclampsia, which is another potential but conflicting cause of cfDNA fetal fraction reduction [31] . Given the small sample size, a multivariable analysis such as a logistic regression and/or a discriminant analysis for risk calculation was not possible, even if the double adjustment (gestational age and maternal weight) reduced the source of bias in cfDNA fetal fraction values.
Conclusion
The data in this study showed a significant association between fetal fraction level in the first trimester and earlyonset FGR. These data are preliminary and require additional research. Given the association between fetal fraction and other markers of preeclampsia and FGR, prospective studies should evaluate the possible contribution of fetal fraction to FGR screening.
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